12 results about "Peptoid" patented technology

Compositions for use in preventing or treating an infection of the nasal passages, sinuses, or both of a subject are described. The compositions include one or more peptoid compounds in an amount effective to prevent or treat the infection in the nasal passages, sinuses, or both. The compositions include the one or more peptoid compounds in an amount effective to inhibit one or more pathogenic bacteria, pathogenic fungus, or pathogenic virus in the nasal passages, sinuses, or both, while having relatively little or no activity against commensal bacterial species, commensal fungal species, commensal viral species, or any combination thereof, in the nasal passages, sinuses, or both of the subject.

The application relates to the technical field of medical materials, and discloses an antibacterial coating containing a peptide-like substance and a preparation method thereof, which comprises the following steps: step 1, preparing an antibacterial solution containing a peptide-like substance; step 2, cleaning and drying the surface of a medical material; step 3, immersing the medical material treated in step 2 in the antibacterial solution in step 1 and standing, then taking out and drying the medical material, and preparing the antibacterial coating on the surface of the medical material; the antibacterial solution containing the peptide-like substance comprises the following raw material components according to 100% by mass: 0.1-2% of a peptide-like substance, 5-20% of tannic acid, 0.5-2% of hydrochloric acid, and the rest is an organic solvent; the peptide-like substance has the following structure. In the application, the peptide-like substance compound with excellent antifungal effect is used in cooperation with natural plant polyphenol tannic acid, the hydrogen bond and the pi-pi stacking between the tannic acid and the peptide-like substance are used together, a hydrophobic antibacterial coating with excellent antibacterial effect, stable adhesion and uniformity is formed on the surface of the medical material.

The present application relates to the technical field of bioengineering, and particularly relates to application of a collagen peptoid in preparation of a vascularized culture system. It is found for the first time that the electrically neutral collagen peptoid containing GER with high GPO monomer proportion has a stable 3D vascularized structure, can be effectively combined with a biomimetic gel component, and is helpful to formation of organoid vascularization. The collagen peptoid has a good industrialization prospect and has a wider application value in the field of medical regeneration.

The present application relates to the technical field of bioengineering, in particular to a collagen peptoid and a preparation method and application thereof. The present application provides a method different from conventional solid-phase synthesis of collagen peptoids. The preparation method of the collagen peptoid provided only needs two-step reactions of polymerization (random polycondensation) and hydrogenation catalysis, and the reactions are carried out in a homogeneous solution, so that the preparation method is simple and suitable for large-scale industrialized preparation. Moreover, the structure of the collagen peptoid provided can be flexibly changed according to needs on the basis of different monomer proportions, and the target peptoid can be quickly prepared.

The present disclosure provides delivery vehicle compositions comprising hydroxyalkyl-capped cationic peptoids, such as 2-aminopropane-1,3-diol-capped cationic peptoids, and complexes of the delivery vehicles with polyanionic compounds, such as nucleic acids. The disclosure further provides methods of making and using the delivery vehicle compositions and complexes, such as for the delivery polyanionic compounds (e.g., nucleic acids) to cells. The disclosure also provides methods of eliciting an immune response with the delivery vehicle complexes of the disclosure.

Compositions are provided which feature mixtures of at least a first and second peptoid. The second peptoid has a terminal aliphatic moiety, while the first peptoid lacks a terminal aliphatic moiety. These compositions have various end uses, including the treatment of various cancers and tumors and the treatment of bacterial, fungal, microbial or parasitic infections.

The application relates to the field of biological medicine, and discloses an antibacterial hydrogel containing a peptoid as well as a preparation method and application thereof, the preparation method comprising the following steps: step 1, adding a catalyst and dopamine hydrochloride into a hyaluronic acid solution to prepare a hyaluronic acid-dopamine precursor solution through reaction; and step 2, mixing a peptoid solution with the precursor solution, and constant-temperature solidification to obtain the antibacterial hydrogel; the structural formula of the peptoid is as follows. In the application, the hyaluronic acid is modified and grafted by using dopamine, and the benzene rings of dopamine and the benzene rings in the peptoid are used to form a multi-component crosslinking network through the joint action of pi-pi stacking and hydrogen bonding, so that a high-stability hydrogel is prepared. The hyaluronic acid is covered on the hydrogel to have excellent biological functionality, the peptoid is covered on the hydrogel to have excellent antibacterial property, the preparation method is simple, raw materials are easy to obtain, and the hydrogel can be applied to the preparation of medical materials for treating wound infection and chronic wound treatment.

This invention relates to the field of organoid culture technology, specifically to the application of a collagen peptide in the preparation of organoid culture systems. This invention discovers that a GER-containing, electrically neutral collagen peptide with a GPO monomer content as high as 40-80% can significantly promote organoid growth, exhibiting a marked promoting effect on organoid proliferation and differentiation. It can effectively combine with biomimetic gels to form organoid culture systems, promoting organoid formation. This invention has good industrialization prospects and broader application value in the field of medical regeneration.

This invention relates to a peptide-like deep eutectic solvent, comprising glycerol, proline, and arginine. The invention utilizes the synergistic effects of glycerol, proline, and arginine to construct a continuous, dense, and dynamically tunable multi-site hydrogen bond network. This hydrogen bond network achieves highly efficient antifreeze protection through both bulk and interfacial mechanisms: at the bulk level, it inhibits ice nucleus formation by disrupting the ordered arrangement of water molecules through competitive hydrogen bonding, and promotes a glass transition during cooling, forming a metastable amorphous matrix that spatially restricts the diffusion and rearrangement of water molecules; at the ice-water interface level, it forms a dynamic adsorption layer that effectively hinders ice crystal growth and recrystallization. This peptide-like deep eutectic solvent achieves highly efficient inhibition of the entire ice crystal formation process, solving the problems of single hydrogen bond networks and insufficient antifreeze regulation in existing deep eutectic solvents. It can be widely applied in antifreeze fields such as food freezing and preservation, and anti-frost and anti-icing coatings.

The present invention relates to a pharmaceutical composition for use in the treatment or prophylaxis of mammary / breast carcinomas, in particular locally recurring or metastasizing mammary carcinomas in a patient or group of patients, who has or is suspected of having a breast carcinoma, comprising at least 4 to 8 HLA-A tumor antigen peptides corresponding to MHC class I complexes and at least 2 tumor antigen peptides corresponding to MHC class II complexes, wherein the HLA tumor antigen peptides are tumor-exclusive or tumor-associated HLA antigen peptides and are directed against at least one MHC complex including combinations thereof; a pharmaceutical composition, a kit (or parts thereof); a method for determining an HLA peptide of class I and / or II; a method for preparing a pharmaceutical composition according to the invention; and the use of a pharmaceutical composition according to the invention for the preparation of a pharmaceutical composition for the treatment of malignancies, leukemias and neoplasms.

The present invention relates to a peptide, a composition comprising the same, and the like. The peptide according to the present invention comprises the following amino acid sequence: an amino acid sequence represented by X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15 (SEQ ID NO. 2) wherein X1 is an arbitrary amino acid or peptoid, X2 is an arbitrary amino acid or peptoid, X3 is an arbitrary amino acid or peptoid, and X4 is an arbitrary amino acid or peptoid. X2 is any amino acid; x3 is an amino acid having an optionally substituted aromatic ring in a side chain; x4 is an amino acid having an optionally substituted aromatic ring in a side chain; x5 is an amino acid having an optionally substituted aromatic ring or an optionally substituted cycloalkyl group in a side chain; x6 is an amino acid having an alkyl group in a side chain; x7 is any secondary amino acid, N-alkyl amino acid or peptoid; x8 is any amino acid; x9 is an amino acid containing an optionally substituted aromatic ring, or an optionally substituted alkyl or cycloalkyl group in a side chain; x10 is R; x11 is an amino acid containing an optionally substituted aromatic ring, or an optionally substituted alkyl group or cycloalkyl group in a side chain; x12 is an optionally substituted aliphatic amino acid, or an amino acid having an optionally substituted alkyl chain in a side chain; x13 is any secondary amino acid, N-alkyl amino acid or peptoid; x14 is an amino acid having an optionally substituted aromatic ring in a side chain; and X15 is any amino acid.